Core Viewpoint - Nanjing Pharmaceutical has signed a joint application agreement with the Military Medical Research Institute of the Chinese People's Liberation Army to apply for a major national science and technology project focused on innovative drug development for high-altitude environment-induced brain edema and pulmonary hypertension [1] Group 1: Collaboration and Strategic Initiatives - The collaboration with the Military Medical Research Institute will strengthen the company's leading position in the cardiovascular disease sector and enhance its innovative drug development capabilities [1] - The company plans to continue increasing its investment in innovative drug research and development to improve its competitiveness in the innovative drug field [1] Group 2: Research and Development Progress - In the first half of 2025, the company's R&D investment reached 47.0095 million yuan, with several projects reaching critical milestones [1] - Key projects include: - Phase II clinical trials for a first-class innovative drug, Mefenamic Acid Tablets, for diabetic nephropathy, which has completed subject enrollment and is entering the data collection and efficacy evaluation phase [1] - The modified new drug, Peramivir inhalation solution, is undergoing Phase III clinical trials, with clinical trials for drug concentration at the target site completed [1] - The oral lyophilized powder for stroke treatment, Dexamethasone, has officially received a clinical trial notification [1] - The nebulized solution of Levosalbutamol has passed on-site verification and completed the acceptance of the market application [1] - The development of projects like Acetaminophen Mannitol Injection is progressing in an orderly manner [1] Group 3: Product Pipeline Optimization - The company is optimizing its product pipeline to leverage existing competitive advantages in known disease areas while exploring potential disease areas, enhancing the resilience of its product pipeline [2] - This strategy is expected to positively impact the company's performance and lay a solid foundation for long-term stable development [2]

Core Insights - Hunan Nanxin Pharmaceutical Co., Ltd. has signed a joint application agreement with the Military Academy of Medical Sciences to apply for a national major science and technology project focused on innovative drug development for high-altitude environment-related conditions [1] - The collaboration aims to strengthen the company's leading position in the cardiovascular disease sector and enhance its innovative drug research and development capabilities [1] - The company plans to increase its investment in innovative drug development to boost its competitiveness in this field [1] Research and Development Progress - In the first half of 2025, the company's R&D investment reached 47.0095 million yuan, with several projects reaching critical milestones [1] - The clinical trial for the innovative drug Meifluorine Hydrochloride Tablets for diabetic nephropathy has completed participant enrollment and is now in the data collection and efficacy evaluation phase [1] - The modified new drug Palivizumab inhalation solution is undergoing Phase III clinical trials, and the first-line stroke treatment drug Difenpyramine oral lyophilized powder has received clinical trial notification [1] - The project for Levosalbutamol nebulized inhalation solution has passed on-site verification and completed the acceptance of market application [1] - Other projects, including Acetaminophen Mannitol Injection, are progressing in an orderly manner [1] Product Pipeline Optimization - The company is optimizing its product pipeline to leverage existing competitive advantages while exploring potential disease areas, which will enhance the resilience of its product pipeline [2] - This strategy is expected to positively impact the company's performance and lay a solid foundation for long-term stable development [2]

Group 1 - The company held its first extraordinary general meeting of shareholders on October 10, 2025, in Guangzhou, China [2] - The meeting was presided over by the chairman, Mr. Zhang Shixi, and utilized a combination of on-site and online voting methods [2][3] - All current directors and supervisors attended the meeting, confirming full participation [3] Group 2 - A key resolution to cancel the supervisory board and amend the company's articles of association was passed with over two-thirds of the voting rights in favor [4][5] - The meeting's procedures and voting results were confirmed to be in compliance with relevant laws and regulations by the witnessing law firm [6] Group 3 - The company announced a share repurchase plan on April 28, 2025, with a budget between RMB 10 million and RMB 20 million, aiming to repurchase shares for employee stock ownership plans [9] - As of September 30, 2025, the company had repurchased 265,516 shares, representing 0.10% of the total share capital, at prices ranging from RMB 7.02 to RMB 7.86 per share, totaling approximately RMB 1.97 million [10] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations [12]

Core Points - Nanjing New Pharmaceutical announced that it has not implemented share repurchase as of September 2025 [2] - As of September 30, 2025, the company has repurchased a total of 265,516 shares through the Shanghai Stock Exchange, which represents 0.10% of the total share capital [2]

湖南南新制药股份有限公司 2025年第一次临时股东大会决议公告 证券代码：688189 证券简称：南新制药 公告编号：2025-046 进行表决。本次会议的召集、召开程序与表决方法、表决程序符合《公司法》《公 司章程》及《上海证券交易所科创板股票上市规则》等法律、法规和规范性文件 的规定。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 10 月 10 日 （二） 股东大会召开的地点：广东省广州市黄埔区开源大道 196 号广州南新制 药有限公司 313 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 211 | | --- | --- | | 普通股股东人数 | 211 | | 2、出席会议的股东所持有的表决权数量 | 102,614,201 | | 普通股股东所持有表决权数量 | 102,614,201 | | 3 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-047 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 265,516股 | | 累计已回购股数占总股本比例 | 0.10% | | 累计已回购金额 | 1,967,393.92元 | | 实际回购价格区间 | 7.02元/股~7.86元/股 | 一、回购股份的基本情况 湖南南新制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第 二届董事会第十五次会议，审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》，同意公司以不低于人民币 1,000 万元（ ...

北京大成（广州）律师事务所 关于湖南南新制药股份有限公司 2025 年第一次临时股东大会的 法律意见书 guangzhou.dachenglaw.com 广州市天河区珠江新城珠江东路 6 号广州周大福金融中心 14 层、15 层（510623） 14/F,15/F CTF Finance Centre No 6 Zhujiang East Road Tianhe District 510623, Guangzhou, China Tel:+8620-85277000 Fax:+8620-85277002 关于湖南南新制药股份有限公司 2025 年第一次临时股东大会法律意见书 北京大成（广州）律师事务所 广州市天河区珠江新城珠江东路 6 号 广州周大福金融中心 14-15 层 北京大成（广州）律师事务所 致：湖南南新制药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公司 股东会规则》等法律、法规和其他有关规范性文件的要求，北京大成（广州）律 师事务所（以下简称"本所"）接受湖南南新制药股份有限公司（以下简称 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.67% on October 10, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haizhu Yueye (Code: 001367) with a closing price of 24.42, up 4.23% [1] - Kangyi Pharmaceutical (Code: 300086) with a closing price of 7.13, up 3.78% [1] - Hanchang Group (Code: 600774) with a closing price of 9.64, up 3.77% [1] - Conversely, significant decliners included: - Nanjing New Pharmaceutical (Code: 688189) with a closing price of 8.01, down 11.98% [2] - Nuocheng Jianhua (Code: 688428) with a closing price of 24.29, down 9.16% [2] - Xiangrikui (Code: 300111) with a closing price of 6.91, down 8.60% [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.305 billion yuan from institutional investors, while retail investors contributed a net inflow of 750 million yuan [2][3] - The top stocks by net inflow from institutional investors included: - Changshan Pharmaceutical (Code: 300255) with a net inflow of 117 million yuan [3] - Yipin Hong (Code: 300723) with a net inflow of 65.62 million yuan [3] - Guangsheng Tang (Code: 300436) with a net inflow of 60.34 million yuan [3]

Core Points - Hunan Nanxin Pharmaceutical Co., Ltd. has experienced a significant stock price decline, with a cumulative drop of 70% over the last 30 trading days, indicating severe abnormal trading fluctuations [2][4] - The company has confirmed that its daily operations are normal, with no significant changes in market conditions or industry policies, and no undisclosed major events [5][6] - As of October 9, 2025, the company's stock price was 9.10 yuan per share, and the rolling price-to-earnings ratio for the pharmaceutical manufacturing industry was 30.49 times, while the company's P/E ratio is negative due to a loss in audited net profit for 2024 [2][10] Abnormal Trading Situation - The stock price has deviated significantly, with a cumulative drop of 70% over 30 trading days, qualifying as severe abnormal trading according to Shanghai Stock Exchange regulations [4] Company Operations and Major Events - The company conducted a self-examination and confirmed that its daily operations are normal, with no major changes or undisclosed significant matters [5][6] - The company received a notice from the China Securities Regulatory Commission regarding a suspected violation of annual report disclosure laws, leading to an investigation [6] - The company has terminated a major asset restructuring agreement with several other pharmaceutical companies [6] Media and Market Rumors - The company has not identified any recent media reports or public rumors that could significantly impact its stock price [8] Sensitive Information - During the period of severe stock price fluctuations, there were no stock trades by the company's directors, supervisors, senior management, or controlling shareholders [9]

Core Viewpoint - Nanjing Pharmaceutical has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report disclosure regulations, which may lead to severe consequences including administrative penalties and potential delisting [1][4][5]. Company Investigation - The CSRC has issued a notice of investigation to Nanjing Pharmaceutical, indicating that the company is suspected of violating information disclosure laws [1]. - During the investigation, the company will cooperate with the CSRC and comply with relevant legal and regulatory requirements for timely disclosures [1][2]. Stock Market Reaction - Following the announcement of the investigation, Nanjing Pharmaceutical's stock hit the daily limit down, closing at 9.1 yuan per share, a decline of 19.96%, with a market capitalization of 2.5 billion yuan [3]. Financial Data Concerns - The investigation primarily focuses on the authenticity of the company's financial data, particularly a correction made in April 2025 regarding the recognition of approximately 24.54 million yuan in revenue from 2023 to 2024 [4]. - Nanjing Pharmaceutical has faced previous regulatory actions for improper accounting treatment related to sales returns, indicating ongoing issues with financial internal controls [4][5]. Performance and Financial Health - Nanjing Pharmaceutical has reported continuous losses since 2021, with revenues declining significantly in 2024, showing a drop of over 60% compared to the previous year [8][10]. - The company's revenue figures from 2021 to 2024 are 744 million yuan, 699 million yuan, 720 million yuan, and 263 million yuan, respectively, with net losses increasing to 357 million yuan in 2024 [8][10]. Product and Market Dynamics - The company's core product, Palivizumab Sodium Injection, saw a significant sales increase in 2023, reaching 667 million yuan, but faced a price drop of over 40% in 2024 due to market competition [12][13]. - The decline in sales and profitability is attributed to reduced demand for flu medications and ongoing issues with the profitability of antibiotic products, which have been under scrutiny by regulators [12][14].